American Diabetes Association
3 files

Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients with Type 2 Diabetes: Results from the Randomized Open Label PDF Study

posted on 2022-08-19, 15:06 authored by Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho



To investigate the effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring (isCGM) in patients with type 2 diabetes mellitus (T2D).


We conducted a 12-week, open-label, randomized controlled trial. A total of 126 participants were 1:1 randomized to either the intervention group (structured education + isCGM) or the control group (standard care with blood glucose monitoring). The Self-Evaluation Of Unhealthy foods by Looking at the postprandial glucose (SEOUL) algorithm was developed and applied to aid structured education by guiding patients to follow healthy eating behavior depending on the postprandial glycemic response. The primary endpoint was the change in HbA1c level from baseline.


Implementation of the SEOUL algorithm with isCGM was associated with a greater improvement in HbA1c than standard care (risk-adjusted difference, –0.50%, 95% CI, –0.74 to –0.26%, P < 0.001). Participants in the intervention group had a greater reduction in fasting blood glucose and body weight (−16.5 mg/dL, 95% CI, −30.0 to −3.0 mg/dL, P = 0.017; −1.5 kg, 95% CI, −2.7 to −0.3 kg, P = 0.013, respectively). The score sum for the Korean version of the revised summary of diabetes self-care activities increased in both groups but to a greater extent in the intervention group (mean difference 4.8, 95% CI, 1.7–8.0, P = 0.003). No severe hyperglycemia or hypoglycemia was reported in either group of patients.


Patient-driven lifestyle modification primarily focused on eating behavior using isCGM effectively lowered HbA1c levels in patients with T2D. 


Y.M.C. received grant funding from Daewoong Pharmaceuticals Co., Ltd. to conduct the study. Daewoong Pharmaceuticals Co., Ltd. provided the CGM devices but had no approval authority for the manuscript before submission, including no right to veto publication.